Trial Profile
An Open Phase I/IIa Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intraveneous BI 6727 as Monotherapy or in Combination With Subcutaneous Cytarabine in Patients With Acute Myeloid Leukaemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Oct 2023
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; Volasertib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 23 Feb 2023 According to a VBL Therapeutics media release, results are expected in 3Q 2024.
- 29 Apr 2021 Status changed from active, no longer recruiting to completed.
- 20 Apr 2021 Planned End Date changed from 5 Apr 2021 to 22 Apr 2021.